Clinical development failure
Drug candidates may not demonstrate safety or efficacy in human studies.
- Scope
- TRPV1-based obesity and erythromelalgia programs
- Materiality
- high
Pila Pharma
PILA PHARMA AB is a Swedish biotech company focused on developing oral drug candidates based on TRPV1 inhibition. The company operates through a parent company in Malmö and a wholly owned Danish subsidiary that carries out research and development activities.
| % | |
|---|---|
| Drug discovery and preclinical development | 70% Discovery and preclinical work on novel oral drug candidates built around TRPV1 inhibition. |
| Clinical development preparation | 20% Activities supporting transition from preclinical work into clinical-stage programs. |
| Intercompany R&D services | 10% Services provided by the parent company to the Danish subsidiary within the group. |
PILA PHARMA does not sell a broad commercial product portfolio; its direct counterparties are primarily the group’s own...
- Intra-group R&D fundingprimary
Pila Pharma Danmark ApS receives research and development support from the parent company.
- Future pharmaceutical partnerssecondary
Potential licensing or collaboration partners for pipeline assets and clinical programs.
- Clinical research organizationssecondary
Contract research providers used to execute outsourced preclinical and clinical work.
- Capital market investorsprimary
Equity investors fund development activities before any product commercialization.
The company is headquartered in Malmö, Sweden, and is organized as a Swedish parent company with a wholly owned Danish...
- •Head office in Malmö, Sweden
- •Wholly owned subsidiary in Denmark
- •R&D activities are centered in the Danish subsidiary
- •Commercial opportunity is global if programs reach partnering or approval
The company’s strategy is to advance its TRPV1-based oral drug platform through preclinical work and into clinical...
01
Move preclinical assets into the clinicshort-term
Clinical entry is the key value inflection point for a development-stage biotech.
02
Build the obesity programmedium-term
Obesity is a large therapeutic market that can support meaningful partnering interest.
03
Advance erythromelalgia as a rare-disease opportunitymedium-term
Rare-disease programs can offer clearer clinical positioning and differentiated value.
As a pre-commercial biotech, PILA PHARMA depends on successful research outcomes, regulatory progress, and access to...
Dependence on external financing
The company is not yet commercial and must fund R&D before product revenue exists.
- Scope
- Research and development operations
- Materiality
- high
Concentration in a single scientific platform
The pipeline is centered on TRPV1 inhibition, so setbacks affect the whole company.
- Scope
- Pipeline and valuation
- Materiality
- high
Outsourcing and consultant dependence
Operations are run through consultants and CROs rather than a large internal team.
- Scope
- Preclinical and clinical execution
- Materiality
- medium
R&D expense recognition
Affects operating result and comparability across periods
Intercompany service revenue
Affects reported operating income at the parent level
Intangible asset impairment
Could materially change reported assets and earnings
Going-concern and liquidity disclosures
Important for assessing solvency and future dilution risk
: 11/08/2026